Achieving Targeted Treatment Outcomes in IBD : Episode 6

Opinion

Video

July 29, 2024

Unmet Needs and Starting Advanced Treatment in Inflammatory Bowel Disease

Author(s):

Silvio Danese, MD, PhD ,Bruce Sands, MD

Silvio Danese, MD, PhD; Bruce Sands, MD, and Jean-Frederic Colombel, MD, highlight the common practice in many community settings of treating inflammatory bowel disease (IBD) with corticosteroids, with or without 5-aminosalicylic acid, and cycling patients through this regimen for prolonged periods, while emphasizing the significant impact and toxicities associated with this treatment approach.

EP: 1.Treat-to-target in Inflammatory Bowel Disease

EP: 2.Recommended Targets When Treating Ulcerative Colitis/Crohn’s Disease in Clinic

EP: 3.Transmural Healing and Monitoring in Ulcerative Colitis and Crohn’s Disease

EP: 4.Implementing Treat to Target in the Long-term in Inflammatory Bowel Disease

EP: 5.Suboptimal Treatment of Inflammatory Bowel Disease in Clinical Practice

EP: 6.Unmet Needs and Starting Advanced Treatment in Inflammatory Bowel Disease

EP: 7.Considerations for Choosing Advanced Treatments and Setting Patient Expectations

EP: 8.Combination Therapy in Inflammatory Bowel Disease

EP: 9.Measuring Patient Satisfaction with Inflammatory Bowel Disease Treatments and Communication Regarding Treatment Changes

When should clinicians start thinking about starting advanced targeted therapies for patients with UC or CD?

Related Videos

Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA

Christine Frissora, MD | Credit: Weill Cornell

Hope on the Horizon: 2 Food Allergy Breakthroughs in 2024

4 experts are featured in this series.

4 experts are featured in this series.

4 experts are featured in this series.

4 experts are featured in this series.

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.